Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.

Genes (Basel) · 2019 · PMC6723793 · PMID 31398933

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

cancer patients who received a single cycle of 75 mg/m 2 of docetaxel monotherapy, the ABCC2 variant rs12762549 showed a trend towards reduced docetaxel clearance, but no association with neutropenia was observed [ 20 ].

also in 53,322 other papers

a strong trendno p-value reported

Finally, there was a strong trend toward patients carrying the 2677TT-3435TT diplotype having higher grades of neutropenia.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.